Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report report published on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald increased their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. HC Wainwright started coverage on Vanda Pharmaceuticals in a research report on Thursday, October 31st. They set a “buy” rating and a $18.00 price objective on the stock.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $5.00 on Friday. The company has a 50 day moving average price of $4.80 and a 200-day moving average price of $5.26. Vanda Pharmaceuticals has a fifty-two week low of $3.32 and a fifty-two week high of $6.75. The stock has a market capitalization of $291.55 million, a PE ratio of -17.86 and a beta of 0.77.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its position in shares of Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Panagora Asset Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,509 shares during the last quarter. Verition Fund Management LLC grew its stake in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 4,374 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.